Aluminum and neurodegenerative disease: therapeutic implications.
McLachlan
D R
DR
Kruck
T P
TP
VanBerkum
M F
MF
D000535:Aluminum / Q000378:metabolism / Q000633:toxicity*; D000544:Alzheimer Disease / Q000188:drug therapy / Q000209:etiology; D000690:Amyotrophic Lateral Sclerosis / Q000209:etiology; D000818:Animals; D001921:Brain / Q000187:drug effects; D002118:Calcium / Q000378:metabolism; D003676:Deferoxamine / Q000627:therapeutic use; D003704:Dementia / Q000209:etiology; D004314:Down Syndrome / Q000209:etiology; D006141:Guam; D006801:Humans; D009422:Nervous System Diseases / Q000139:chemically induced*; D009454:Neurofibrils / Q000187:drug effects; D009474:Neurons / Q000187:drug effects; D018377:Neurotransmitter Agents / Q000037:antagonists & inhibitors; D010302:Parkinson Disease, Secondary / Q000209:etiology
D018377:Neurotransmitter Agents; D000535:Aluminum; D003676:Deferoxamine; D002118:Calcium